RoyB.JonesMD

Oncology • Houston, TX

Physician

Join to view full profile

Are you Dr. Jones?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 77 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161
Is this information wrong?

Summary

Dr. Roy Jones, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Colorado, and New York. He is affiliated with University of Texas M.D. Anderson Cancer Center.

Education & Training

National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1976 - 1979
Duke University HospitalInternship, Internal Medicine, 1975 - 1976
Duke University School of MedicineClass of 1975

Certifications & Licensure

NY State Medical License 1980 - Present
TX State Medical License 2002 - 2024
CO State Medical License 1990 - 2003
NC State Medical License 1975 - 2002
MD State Medical License 1977 - 1980
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies Start of enrollment: 2007 Aug 01
Completed
Phase 1

Publications & Presentations

PubMed

14 citations
Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial.
Sairah Ahmed, Qaiser Bashir, Roland L. Bassett, Man Yin C. Poon, Ben C. Valdez, Sergej Konoplev, Amin M. Alousi, Borje S. Andersson, Stefan O. Ciurea, Chitra Hosing, R...> ;Transplantation and Cellular Therapy. 2021 May 1
19 citations
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation.
Amanda Olson, Ruitao Lin, David Marin, Hind Rafei, Mustafa Bdaiwi, Peter F. Thall, Rafet Basar, Ala Abudayyeh, Pinaki P. Banerjee, Fleur M. Aung, Indresh Kaur, Glorett...> ;Journal of Clinical Oncology. 2021 Apr 30
15 citations
Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD
Rohtesh S. Mehta, Roland L. Bassett, Gabriela Rondon, Bethany J. Overman, U. Popat, Chitra Hosing, Katy Rezvani, Muzaffar H. Qazilbash, P. Anderlini, Roy B. Jones, Par...> ;Bone Marrow Transplantation. 2021 Jan 4
11 citations
Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial
Uday R. Popat, Rohtesh S. Mehta, Roland L. Bassett, Piyanuch Kongtim, Julianne Chen, Amin M. Alousi, Paolo Anderlini, Stefan O. Ciurea, Chitra Hosing, Roy B. Jones, Pa...> ;Biology of Blood and Marrow Transplantation. 2020 Aug 1
Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients.
Ala Abudayyeh, Heather Lin, Maen Abdelrahim, Gabriela Rondon, Borje S. Andersson, Charles Martinez, Valda D. Page, Jeffrey J. Tarrand, Dimitrios P. Kontoyiannis, David...> ;Transplant Infectious Disease. 2020 Jul 14
7 citations
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
Gheath Alatrash, Kelly M. Kidwell, Peter F. Thall, Antonio Di Stasi, Julianne Chen, Madhushree Zope, Alyssa K. Crain, Richard E. Champlin, Uday R. Popat, Elizabeth J. ...> ;Bone Marrow Transplantation. 2019 Aug 1
22 citations
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified...
Uday R. Popat, Rohtesh S. Mehta, Roland L. Bassett, Julianne Chen, Benigno C. Valdez, Jitesh D. Kawedia, Sairah Ahmed, Amin M. Alousi, Paolo Anderlini, Geath Al-Atrash...> ;The Lancet. Haematology. 2018 Nov 1
12 citations
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Yago Nieto, Peter F. Thall, Junsheng Ma, Benigno C. Valdez, Sairah Ahmed, Paolo Anderlini, Uday R. Popat, Roy B. Jones, Elizabeth J. Shpall, Chitra Hosing, Muzaffar H....> ;Biology of Blood and Marrow Transplantation. 2018 Aug 1
4 citations
Stem Cell Transplantation and Informatics: Current Considerations
Roy B. Jones, Charles Martinez, Navneet S. Majhail, Matthew Prestegaard, Martin Maiers, Mitchell E. Horwitz, Krishna V. Komanduri> ;Biology of Blood and Marrow Transplantation. 2017 Dec 1
16 citations
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair co...
Yago Nieto, Benigno C. Valdez, Sai Ravi Pingali, Roland L. Bassett, Ruby Delgado, John Nguyen, Nina Shah, Uday R. Popat, Roy B. Jones, Borje S. Andersson, Alison M. Gu...> ;The Lancet. Haematology. 2017 Jun 1
9 citations
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin ly...
Samer A. Srour, Shaoying Li, U. Popat, Muzaffar H. Qazilbash, Sara Lozano-Cerrada, Farzeneh Maadani, Amin M. Alousi, Partow Kebriaei, P. Anderlini, Yago Nieto, Roy B. ...> ;British Journal of Haematology. 2017 May 9
49 citations
Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
Borje S. Andersson, Peter F. Thall, Ben C. Valdez, Denái R. Milton, Gheath Alatrash, J. Chen, Alison M. Gulbis, Diem T. Chu, Charles Martinez, Simrit Parmar, Uday R. P...> ;Bone Marrow Transplantation. 2017 Apr 1
13 citations
Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients.
Ala Abudayyeh, Amir Hamdi, Maen Abdelrahim, Heather Lin, Valda D. Page, Gabriela Rondon, Borje S. Andersson, Aimaz Afrough, Charles Martinez, Jeffrey J. Tarrand, Dimit...> ;Transplant Infectious Disease. 2017 Feb 1
21 citations
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Lo...
Partow Kebriaei, Roland L. Bassett, Genevieve Lyons, Ben C. Valdez, Celina Ledesma, Gabriela Rondon, Betul Oran, Stefan O. Ciurea, Amin M. Alousi, Uday R. Popat, Krina...> ;Biology of Blood and Marrow Transplantation. 2017 Feb 1
35 citations
Double epigenetic modulation of high‐dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor‐risk relapsed lymphoma
Yago Nieto, Benigno C. Valdez, Peter F. Thall, Roy B. Jones, Wei Wei, Alan L. Myers, Chitra Hosing, Sairah Ahmed, Uday R. Popat, Elizabeth J. Shpall, Muzaffar H. Qazil...> ;Cancer. 2016 Sep 1
Patient safety and institutional review boards in multi-institutional dose escalation or expansion trials.
Roy B. Jones> ;The Lancet. Oncology. 2016 Sep 1
47 citations
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation
Takuya Sekine, David Marin, Kai Cao, Li Li, Pramod Mehta, Hila Shaim, Catherine Sobieski, Roy B. Jones, Betul Oran, Chitra Hosing, Gabriela Rondon, Abdullah Alsuliman,...> ;Blood. 2016 Jul 14
76 citations
IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation
Anushruti Sarvaria, Rafet Basar, Rohtesh S. Mehta, Hila Shaim, Muharrem Muftuoglu, Ahmad Khoder, Takuye Sekine, Elif Gokdemir, Kayo Kondo, David Marin, May Daher, Amin...> ;Blood. 2016 Sep 8
7 citations
Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation.
Ankur Varma, Rima M. Saliba, Harrys A. Torres, Aimaz Afrough, Chitra Hosing, Issa F. Khouri, Yago Nieto, Nina Shah, Simrit Parmar, Qaiser Bashir, Sairah Ahmed, Roy B. ...> ;Bone Marrow Transplantation. 2016 Jul 1
14 citations
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leuke...
Gheath Alatrash, Peter F. Thall, Benigno C. Valdez, Patricia S. Fox, Jing Ning, Haven R. Garber, Selma Janbey, Laura L. Worth, Uday R. Popat, Chitra Hosing, Amin M. Al...> ;Biology of Blood and Marrow Transplantation. 2016 Oct 1
Disseminated Cryptococcal Infection in Allogeneic Stem Cell Transplant Patients: A Rare Cause of Acute Kidney Injury
R Jones, W Glass, P Kebriaei, V E Mulanovich, A Tchakarov, A Abudayyeh, J Samuels, D P Kontoyiannis> ;Nature. 2016-10-01
36 citations
Symptomatic BK virus infection is associated with kidney function decline and poor overall survival in allogeneic hematopoietic stem cell recipients
Ala Abudayyeh, Amir Hamdi, Huei K. Lin, Maen Abdelrahim, Gabriella Rondon, Borje S. Andersson, Aimaz Afrough, Charles Martinez, Jeffrey J. Tarrand, Dimitrios P. Kontoy...> ;American Journal of Transplantation. 2016 May 1
8 citations
Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients
Samuel L. Aitken, Jian Zhou, Shashank S. Ghantoji, Dimitrios P. Kontoyiannis, Roy B. Jones, Vincent H. Tam, Roy F. Chemaly> ;The Journal of Antimicrobial Chemotherapy. 2016 Mar 1
11 citations
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia
Fleur M. Aung, Benjamin Lichtiger, Gabriela Rondon, C. Cameron Yin, Amin M. Alousi, Sairah Ahmed, Borje S. Andersson, Qaiser Bashir, Stefan O. Ciurea, Chitra Hosing, R...> ;Biology of Blood and Marrow Transplantation. 2016 May 1
9 citations
Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refrac...
Keiji Shinozuka, Hongwei Tang, Roy B. Jones, Donghui Li, Yago Nieto> ;Biology of Blood and Marrow Transplantation. 2016 May 1
Join now to see all

Grant Support

Phase I Studies For Patients With Breast CancerNational Cancer Institute1994–1997
Imaging/Treatment Of Advanced Breast Cancer With Yttrium 90 Bre3 RadiolabeledNational Center For Research Resources1996
Imaging/Treatment Of Advanced Breast Cancer With Yttrium-90 Bre-3 RadiolabeledNational Center For Research Resources1994–1995

Hospital Affiliations

University of Texas M.D. Anderson Cancer CenterHouston, Texas